BIOMAT Database Logo BIOMAT Database Logo

[Clinical evaluation of radiosensitizing effects of misonidazole]. 1984

N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008920 Misonidazole A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic. Ro 07-0582,Ro 7-0582,alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol,Ro 07 0582,Ro 070582,Ro 7 0582,Ro 70582
D009593 Nitroimidazoles IMIDAZOLES having a nitro moiety. Nitroimidazole
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Teratogenic and radiosensitizing effects of misonidazole on mouse embryos.
February 1981, The British journal of radiology,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Radiosensitizing and cytocidal effects of misonidazole: evidence for separate modes of action.
July 1987, Radiation research,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
[The radiosensitizing effects of misonidazole and/or 5FU on C3H mouse mammary carcinoma].
September 1985, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
[Studies in radiosensitizing effects of misonidazole and SR-2508 on experimental animal tumors].
February 1983, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
[Radiosensitizing effect of misonidazole in radiotherapy for intracranial tumors].
November 1982, Nihon geka hokan. Archiv fur japanische Chirurgie,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Cytotoxic and radiosensitizing effects of misonidazole on hematopoiesis in normal and tumor-bearing mice.
September 1980, International journal of radiation oncology, biology, physics,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
A metabolite of the 2-nitroimidazole misonidazole with radiosensitizing properties.
July 1978, International journal of radiation biology and related studies in physics, chemistry, and medicine,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
January 1984, Radiation medicine,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Mechanism of action of nitroimidazole antimicrobial and antitumour radiosensitizing drugs. Effects of reduced misonidazole on DNA.
October 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine,
N Mitsuhashi, and I Yonome, and H Niibe, and K Mogi, and K Sakaino, and N Nakajima, and K Saito, and Y Suzuki, and H Sudo, and A Okazaki
Azomycin riboside, a sugar homologue of misonidazole with favorable radiosensitizing properties.
November 1982, Cancer research,
Copied contents to your clipboard!